Other compounds under investigation or in any of the experimental phases by the FDA include elafibranor for PPARα/δ (Schattenberg et al., 2021), telmisartan and fimasartan for PPARγ/AT1 (Seo et al., 2022), lanifibranor and sodelglitazar for PPARα/δ/γ (Kamata et al., 2023) and licogliflozin and sotagliflozin for SGLT1-2, the latter already approved by the FDA in 2023 to reduce the risk of cardiovascular death and heart failure in adults with heart failure, T2DM, chronic kidney disease, and other cardiovascular risk factors (Packer, 2023). Here, PPARA is linked to chronic kidney disease.